Is ONCY a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

988 people get ONCY articles and Market Currents by email alert.

Get email alerts on ONCY »

HEADLINES:

Oncolytics Biotech's CEO Presents at 2013 Annual Meeting of Shareholders Conference (Transcript)
Sat, May 11
Oncolytics Biotech® Inc. Announces Director Election Results from its Annual and Special Meeting of Shareholders

PR Newswire (May 10, 2013)
Oncolytics Biotech® Inc. Announces First Quarter 2013 Results

PR Newswire (May 9, 2013)
Oncolytics Biotech® Inc. Announces Details of 2013 Annual and Special Meeting of Shareholders

PR Newswire (May 6, 2013)
Oncolytics: A Failing Biopharma, Or An Opportune Buy?
Healthcare Specialist • Mon, Apr 8 • 13 Comments
Oncolytics Biotech® Inc. Meets Primary Overall Statistical Endpoint in U.S. Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer

PR Newswire (Mar 28, 2013)
Oncolytics Biotech® Inc. Announces 2012 Year End Results

PR Newswire (Mar 14, 2013)
Oncolytics Biotech® Inc. Completes Patient Enrollment in U.S. Phase 2 Study of REOLYSIN® in Non-Small Cell Lung Cancer

PR Newswire (Mar 5, 2013)
Oncolytics' Rough Ride
Snefix • Tue, Mar 5 • 1 Comment
Oncolytics Biotech® Inc. Announces Closing of Common Share Offering

PR Newswire (Feb 25, 2013)
Oncolytics Biotech® Inc. Announces Addition to Senior Management Team

PR Newswire (Feb 20, 2013)
Oncolytics Biotech® Inc. Announces Pricing of Common Share Offering

PR Newswire (Feb 20, 2013)
Oncolytics Biotech® Inc. Announces Common Share Offering

PR Newswire (Feb 19, 2013)
Oncolytics Biotech Poised To Climb
Snefix • Tue, Feb 12 • 4 Comments
Oncolytics Moves On A Hot Streak Of Clinical Data
Brian L. Wilson • Tue, Feb 12 • 4 Comments
Oncolytics Biotech, Inc.: An Intro To These Next Few Crucial Weeks
Michelle Gilson • Mon, Feb 11 • 85 Comments
Oncolytics Biotech Shares Soar On Reolysin Trial Success
Maani Value Guru • Fri, Feb 8 • 28 Comments
Oncolytics Biotech® Inc. Announces Additional Positive REOLSYIN® Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung

PR Newswire (Feb 8, 2013)
3 Small-Cap Biotechs Possessing Zero Debt And Long-Term Potential
Matt Schilling • Thu, Jan 31 • 12 Comments
Oncolytics Biotech® Inc. Announces Positive REOLSYIN® Clinical Trial Data Presented at ASCO Gastrointestinal Cancers Symposium

PR Newswire (Jan 28, 2013)

To learn more about Seeking Alpha Pro, click here.

Oncolytics: A Failing Biopharma, Or An Opportune Buy?
Healthcare Specialist • Mon, Apr 8 • 13 Comments
Oncolytics' Rough Ride
Snefix • Tue, Mar 5 • 1 Comment
Oncolytics Biotech Poised To Climb
Snefix • Tue, Feb 12 • 4 Comments
Oncolytics Moves On A Hot Streak Of Clinical Data
Brian L. Wilson • Tue, Feb 12 • 4 Comments
Oncolytics Biotech, Inc.: An Intro To These Next Few Crucial Weeks
Michelle Gilson • Mon, Feb 11 • 85 Comments
Oncolytics Biotech Shares Soar On Reolysin Trial Success
Maani Value Guru • Fri, Feb 8 • 28 Comments
Oncolytics Biotech: What Is All The Excitement About?
C.R. Jackson • Tue, Dec 18, 2012 • 2 Comments
Oncolytics Sharply Overvalued Following REO 018 Trial Failure
Apsara Biotechnology Research • Mon, Sep 17, 2012 • 23 Comments
Investors Left Waiting For Data At Oncolytics
Chimera Research Group • Tue, Sep 11, 2012 • 12 Comments
Oncolytics Pushes Its Pipeline Further
M. E. Garza • Thu, Dec 2, 2010 • 4 Comments
Pivotal Cancer Treatment: Oncolytics Likely to Succeed
Chinook Traveler • Mon, Mar 23, 2009 • 3 Comments
Oncolytics Announces Breakthrough in Cancer Treatment Trials
FP Trading Desk • Thu, May 22, 2008 • 6 Comments

3 Small-Cap Biotechs Possessing Zero Debt And Long-Term Potential
Matt Schilling • Thu, Jan 31 • 12 Comments
5 Biotech Stocks To Watch Under $5
Nathaniel Matherson • Mon, Jan 7 • 14 Comments
5 Stocks Under $5 On Winning Streaks
Kapitall • Sat, Jan 5 • 9 Comments
5 Highly Liquid Biotech Stocks Positively Correlated To Volatility
Kapitall • Mon, Aug 27, 2012 • 3 Comments
Hyper-Novel Investments For Targeting Cancer
A John Hodge • Wed, May 30, 2012 • 3 Comments
Baker's Dozen Trying To Beat The Odds In Pancreatic Cancer
Michael Becker • Tue, Oct 25, 2011 • 6 Comments
6 Micro-Cap Biotech Stocks Enjoying Winning Streaks
Kapitall • Thu, Aug 25, 2011 • 1 Comment
Cramer's Mad Money - My Most Unpopular Call in the Last Six Years (4/7/11)
SA Editor Miriam Metzinger • Fri, Apr 8, 2011 • 17 Comments
4 Biotech Companies With a 2-Year Cash Cushion, Being Snapped Up by the Smart Money
Kapitall • Mon, Mar 28, 2011 • 7 Comments
Why Phase 3 Trials Fail: What Investors Need to Know
Steven Breazzano • Mon, Mar 7, 2011 • 17 Comments
20 Rallying Stocks Being Targeted by Short Sellers
Kapitall • Mon, Jan 3, 2011 • 19 Comments
Momentum Trades: 25 Stocks Hitting New Highs on Institutional Buying
Kapitall • Mon, Dec 13, 2010 • 3 Comments
Amgen, Celgene and Novartis in the Fight Against Pancreatic Cancer
Michael Becker • Tue, Oct 26, 2010 • 7 Comments
The Complete List of Canadian Stocks Traded on the Nasdaq
David Hunkar • Mon, Dec 21, 2009 • 3 Comments
Columbus Day Dash and Slash: DepoMed, Vivus, Oncolytics and RadNet
M. E. Garza • Mon, Oct 12, 2009 • 1 Comment
5 Biotech Stocks to Keep an Eye On
M. E. Garza • Mon, Oct 5, 2009 • 3 Comments
Performance Review of Our Swing Trading Signals
Trade Radar Operator • Mon, Jun 8, 2009
Biotech IPO: BioVex Group Files S-1 (BVEX)
SA Editor Abbi Adest • Sun, Jun 25, 2006

Oncolytics Biotech's CEO Presents at 2013 Annual Meeting of Shareholders Conference (Transcript)
Sat, May 11

Oncolytics Biotech® Inc. Announces Director Election Results from its Annual and Special Meeting of Shareholders

PR Newswire (May 10, 2013)
Oncolytics Biotech® Inc. Announces First Quarter 2013 Results

PR Newswire (May 9, 2013)
Oncolytics Biotech® Inc. Announces Details of 2013 Annual and Special Meeting of Shareholders

PR Newswire (May 6, 2013)
Oncolytics Biotech® Inc. Meets Primary Overall Statistical Endpoint in U.S. Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer

PR Newswire (Mar 28, 2013)
Oncolytics Biotech® Inc. Announces 2012 Year End Results

PR Newswire (Mar 14, 2013)
Oncolytics Biotech® Inc. Completes Patient Enrollment in U.S. Phase 2 Study of REOLYSIN® in Non-Small Cell Lung Cancer

PR Newswire (Mar 5, 2013)
Oncolytics Biotech® Inc. Announces Closing of Common Share Offering

PR Newswire (Feb 25, 2013)
Oncolytics Biotech® Inc. Announces Addition to Senior Management Team

PR Newswire (Feb 20, 2013)
Oncolytics Biotech® Inc. Announces Pricing of Common Share Offering

PR Newswire (Feb 20, 2013)
Oncolytics Biotech® Inc. Announces Common Share Offering

PR Newswire (Feb 19, 2013)
Oncolytics Biotech® Inc. Announces Additional Positive REOLSYIN® Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung

PR Newswire (Feb 8, 2013)
Oncolytics Biotech® Inc. Announces Positive REOLSYIN® Clinical Trial Data Presented at ASCO Gastrointestinal Cancers Symposium

PR Newswire (Jan 28, 2013)
Oncolytics Biotech Inc. Announces Positive Top Line REOLYSIN® Data for First Endpoint in Randomized Phase III Study in Head and Neck Cancers

PR Newswire (Dec 13, 2012)
Oncolytics Biotech Inc. Announces Addition to Senior Management Team

PR Newswire (Nov 12, 2012)
Oncolytics Biotech® Inc. Collaborators Present Positive REOLYSIN® Trial Results and Research at EORTC-NCI-AACR Symposium

PR Newswire (Nov 9, 2012)
Oncolytics Biotech® Inc. Announces Third Quarter 2012 Results

PR Newswire (Nov 8, 2012)
Oncolytics Biotech® Inc. Completes Patient Enrollment in U.S. Phase II Clinical Trial Investigating REOLYSIN® in Combination with Gemcitabine in Patients with Advanced or Metastatic Pancreatic Cancer

PR Newswire (Oct 24, 2012)
Oncolytics Biotech Inc. Announces the Appointment of Dr. Alan J. Tuchman as Chief Medical Officer

PR Newswire (Sep 28, 2012)
Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Squamous Cell Lung Cancer Clinical Trial

PR Newswire (Sep 13, 2012)
Movers & Shakers: Wednesday’s biggest gaining and declining stocks

at MarketWatch.com (Sep 12, 2012)

ONCY vs. ETF Alternatives

Company Description

Currently, there's no company description for ONCY.

Sector: Healthcare

Industry: Biotechnology

Country: Canada

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, March 28, 9:29 AM Oncolytics Biotech (ONCY) +8.7% premarket after announcing positive results from a midstage study of its lead product candidate Reolysin in treating squamous cell carcinoma of the lung. A sufficient number of responses in the first stage of the study were seen to proceed with enrollment in the second stage. Comment! [Healthcare, On the Move]
Thursday, March 28, 9:10 AM Premarket gainers: RPRX +75%. CTIC +14%. ONCY +8%. EXM +7%. DECK +6%. XONE +6%.
Losers: TWO -8%. FIVE -7%. GME -5%. 1 Comment [On the Move]
Monday, February 25, 12:36 PM Oncolytics Biotech (ONCY -1.5%) dips after closing out its previously announced underwritten public offering of 8M shares at $4. The company intends to use the net proceeds from the offering to fund its clinical trial and manufacturing program. 1 Comment [Healthcare, On the Move]
Wednesday, February 20, 12:45 PM Midday top 10 gainers: NVGN +46%. IMMY +33%. IKNX +29%. NTSP +29%. CRTX +22%. LZB +17%. CHLN +16%. RVLT +15%. CMGE +14%. TCX +14%.
Midday top 10 losers: HNR -39%. MM -36%. GMXR -19%. MEIL -19%. JAXB -18%. ANAD -16%. ODP -14%. ONCY -13%. BONE -13%. COBR -12%. Comment! [On the Move]
Wednesday, February 20, 10:22 AM Shares of Oncolytics Biotech (ONCY -13.8%) tank on resumption of trading after pricing its 8M share offering at $4, a 14% discount to Tuesday's close. The drug developer's shares were halted in premarket trading as the company disclosed the details. The company, which had had about 76.8M shares outstanding before today, unveiled the offering yesterday to raise funds for its clinical-trials and manufacturing programs. 1 Comment [Healthcare, On the Move]
Wednesday, February 20, 9:10 AM Premarket gainers: NTSP +30%. NVGN +14%. JASO +9%. SINA +8%. GDOT +8%. THLD +8%. RMBS +8%. OMX +7%. ODP +7%. MDRX +6%. GALE +5%.
Losers: HNR -41%. MM -27%. ONCY -12%. GRMN -9%. LIFE -5%. Comment! [On the Move]
Tuesday, February 19, 6:27 PM Oncolytics Biotech (ONCY) initiates a public stock offering for an undetermined amount of shares. The company says the size and price of the offering are to be determined at the time of pricing. It intends to use the net proceeds to fund its clinical trial program, manufacturing program and for general corporate and working capital purposes. Shares -7% AH. Comment! [Healthcare, On the Move]
Monday, February 11, 3:02 PM A genetically modified smallpox vaccine has been shown to shrink tumors in liver cancer patients and extends survival more than a year, a recent study found. The therapy, from closely held Jennerex, is called JX-594, or Pexa-Vec, and is currently being tested in people with advanced hepatocellular carcinoma. Treatment options for this advanced type of cancer are limited, and San Francisco-based Jennerex is competing with drug behemoths such as Amgen (AMGN -1.5%) and Merck (MRK +0.4%) in the space, as well as others such as Oncolytics Biotech (ONCY -5%) and Dendreon (DNDN -3.3%). 6 Comments
Friday, February 8, 1:00 PM Midday top 10 gainers: BDCO +32%. CZR +25%. ONCY +23%. LNKD +20%. SNCR +19%. GALT +13%. ZN +13%. FLT +12%. ZNGA +12%. ATVI +11%.
Midday top 10 losers: ETRM -55%. MSON -22%. GUID -21%. NUAN -19%. RVBD -18%. QKLS -16%. JE -14%. NSP -13%. STS -11%. SPWR -10%. Comment! [On the Move]
Friday, February 8, 9:07 AM Oncolytics Biotech (ONCY) +35.3% premarket after announcing positive results from a mid-stage clinical trial examining the use of its lead product candidate Reolysin in helping shrink tumors. ONCY says 95% of patients with squamous cell carcinoma of the lung using Reolysin intravenously in combination with carboplatin and paclitaxel exhibited overall tumor shrinkage. Comment! [Healthcare, On the Move]
Monday, January 28, 12:32 PM Oncolytics Biotech (ONCY -0.7%) announces preliminary results from a Phase I study examining the intravenous administration of Reolysin in combination with Folfiri in patients with metastatic colorectal cancer, saying the combination was safe and well tolerated and resulted in disease control in the majority of evaluable patients. Comment! [Healthcare]
Monday, December 17, 2012, 12:45 PM Midday top 10 gainers: GNVC +37%. CBOU +30%. HRT +16%. CEDC +15%. OCZ +13%. CPWR +13%. ONCY +13%. JVA +12%. VELT +12%. HTCH +12%.
Midday top 10 Losers: SCL -48%. GYRO -31%. END -20%. OPXA -13%. CLWR -12%. XUE -12%. SSE -11%. ALIM -11%. RVM -11%. NBG -9%. 1 Comment [On the Move]
Thursday, December 13, 2012, 12:45 PM Midday top 10 gainers: ONCY +51%. TELK +23%. PRGN +21%. GBR +17%. SDBT +16%. SAM +15%. BBY +15%. CLWR +14%. ZAGG +14%. TROV +13%.
Midday top 10 Losers: RIGL -35%. EVI -31%. HRG -26%. PTIE -19%. CBMX -18%. OSN -15%. MEIP -13%. DQ -12%. CSUN -12%. ALLT -11%. Comment! [On the Move]
Thursday, December 13, 2012, 9:10 AM Premarket gainers: TELK +28%. ONCY +22%. BBY +17%. CLWR +13%. CVS +5%. TSL +5%.
Losers: RIGL -33%. HRG -26%. Comment! [On the Move]
Thursday, December 13, 2012, 8:54 AM Oncolytics Biotech (ONCY) soars 20.3% after saying its Reolysin treatment, in combination with carboplatin and paclitaxel, performed well in a Phase III trial of patients with head and neck cancer. Of 105 patients, 86% exhibited tumour stabilization or shrinkage vs 67% in the control group. The combo including Reolysin was also better at shrinking tumors than the two other treatments on their own. (PR) Comment! [Healthcare, On the Move]
Monday, November 12, 2012, 3:45 PM Oncolytics Biotech (ONCY -2%) says it's appointed Kirk Look as it's new chief financial officer. Mr. Look has served as ONCY's controller since 2003. Comment! [Healthcare, On the Move]

Nathaniel Matherson
Oncolytics Biotech Inc. Short Interest Near Highs $ONCY http://bit.ly/11cl0oe
Apr 1, 12:13 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Snefix
$ONCY down $0.21 (-4.5%) in after hours trading.
Feb 19, 11:57 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

phemale60
$ONCY - saw pre-market soar on study re cancer tumor shrinkage; submitted to enthusiasm and now wonder if can go higher?
Feb 8, 1:15 PM
Reply (12)

• !Report Abuse
View all 12 replies
phemale60: You're right. I saw it up on Sqawk Box ticker 2/8 up and it looked good but was already up too high. Sold some/kept some. Not enuf worth it
Feb 27, 5:42 PM
• !Report Abuse
phemale60: I've about had it with biotechs. Too much stress, gut aches --- I'm too old for this!!! LOL
Feb 27, 5:43 PM
• !Report Abuse
Add a reply...

140 characters

The Scientist
$ONCY potential is huge. Reolysin can also be used for many other cancer types. Following: $CYCC $CYTK $ONCY $SNTA $SRPT $YMI
12/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Combining ONCY Reolysin with THLD TH-302 in pancreatic CA would be an interesting trial. Attacking cancer using totally different modalities
6/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Great cover story in Science Trans Med on ONCY. Reolysin basically a self-perpetuating cancer bomb. Await P3 results. If positive, MA target
6/22/12
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: From a virology/vaccination standpoint, ONCY reovirus much safer than herpesvirus or poxvirus
6/23/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
Here's some stocks ready for a massive squeeze: ABAX CBZ CHUX FRED GHDX HEI INWK ONCY RUTH VIVO http://bit.ly/jHbbfU
6/9/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

PullDaTrigger
$ONCY might break $7 today. Not many shares available, very tight float held by long time retail believers.
1/18/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

PullDaTrigger
Investing in Oncolytics Biotech $ONCY since I believe it will be the biggest story of the coming decade. Institutions are starting to buy.
1/18/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

PullDaTrigger
Oncolytics $ONCY announced randomized phase II trial for pancreatic cancer using virus based treatment. Steve Jobs a potential patient?
1/18/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

phemale60
$ONCY - saw pre-market soar on study re cancer tumor shrinkage; submitted to enthusiasm and now wonder if can go higher?
Feb 8, 1:15 PM
Reply (12)

• !Report Abuse
View all 12 replies
phemale60: You're right. I saw it up on Sqawk Box ticker 2/8 up and it looked good but was already up too high. Sold some/kept some. Not enuf worth it
Feb 27, 5:42 PM
• !Report Abuse
phemale60: I've about had it with biotechs. Too much stress, gut aches --- I'm too old for this!!! LOL
Feb 27, 5:43 PM
• !Report Abuse
Add a reply...

140 characters

The Scientist
Great cover story in Science Trans Med on ONCY. Reolysin basically a self-perpetuating cancer bomb. Await P3 results. If positive, MA target
6/22/12
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: From a virology/vaccination standpoint, ONCY reovirus much safer than herpesvirus or poxvirus
6/23/12
• !Report Abuse
Add a reply...

140 characters

ONCY Oncolytics Biotech, Inc.

ONCY

Oncolytics Biotech, Inc.